Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049686
Status:
COMPLETED
Last Update Posted:
2013-07-18
First Post:
2002-11-12
Brief Title:
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Sponsor:
Vion Pharmaceuticals
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase I Trial Of VNP40101M A Novel Alkylating Agent For Patients With Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2003-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
PURPOSE Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome
PURPOSE Phase I trial to study the effectiveness of VNP40101M in treating patients who have relapsed or refractory leukemia or myelodysplastic syndrome
Detailed Description:
OBJECTIVES
Determine the toxic effects of VNP40101M in patients with relapsed or refractory leukemia or poor-risk myelodysplastic syndromes
Determine the maximum tolerated dose of this drug in these patients
Determine the pharmacokinetics of this drug in these patients
Determine the antitumor effects of this drug in these patients
OUTLINE Patients receive VNP40101M IV over 15 minutes once every 4 weeks
PROJECTED ACCRUAL Approximately 40 patients will be accrued for this study
Determine the toxic effects of VNP40101M in patients with relapsed or refractory leukemia or poor-risk myelodysplastic syndromes
Determine the maximum tolerated dose of this drug in these patients
Determine the pharmacokinetics of this drug in these patients
Determine the antitumor effects of this drug in these patients
OUTLINE Patients receive VNP40101M IV over 15 minutes once every 4 weeks
PROJECTED ACCRUAL Approximately 40 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MDA-DM-02202 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000258354 | REGISTRY | None | None |